Orphazyme co-founder becomes board chair at biotech startup

Anders Hinsby will sit at the head of the table at board meetings for Pephexia Therapeutics.

Anders Hinsby, CEO of Muna Therapeutics and chairman of the board at Pephexia Therapeutics. | Photo: Muna Therapeutics / PR

In 2019, Anders Hinsby left his role as CEO of Orphazyme, a company he helped to establish back in 2010.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs